score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Preclinical	Inferential	Copy Number	ERBB2	Amplification				0.0	0.0		Putatively Actionable	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy.	Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf	Putatively Actionable	Radiation therapy	Radiation	Radiation therapy	Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab.	Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20. 	https://mct.aacrjournals.org/content/2/11/1113.long	Putatively Actionable	0.0	Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).	F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791	https://doi.org/10.1016/S0959-8049(97)10157-5	0				ERBB2 Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Putatively Actionable	Preclinical			Copy Number	AURKB	Amplification				0.0	0.0		Putatively Actionable	Barasertib	Aurora-B kinase inhibition	Targeted therapy	MYC amplified small cell lung cancer	Helfrich BA, Kim J, Gao D, et al. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016;15(10):2314-2322.	https://doi.org/10.1158/1535-7163.MCT-16-0298													0				AURKB Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Putatively Actionable	Preclinical			Copy Number	FGFR1	Amplification				0.0	0.0		Putatively Actionable	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR1 Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Putatively Actionable			Clinical evidence	Copy Number	MYC	Amplification				0.0	0.0																Putatively Actionable	0.0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13.	https://doi.org/10.1007/s00401-011-0923-y	0				MYC Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.R617G	0.4167	24.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf													0	0.0	0.0	0.0	FGFR3 p.R617G (Missense)		KIRP-A4-8630	KIRP-A4-8630-TP	KIRP-A4-8630-NB
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.286						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683													0				COSMIC Signature (version 2) 3 (29%)		KIRP-A4-8630		
Investigate Actionability			Guideline	Copy Number	TP53	Amplification				0.0	0.0																Investigate Actionability	0.0	Deletion of 17p13 leads to LoH of TP53 and is considered a high-risk feature of multiple myeloma.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	0				TP53 Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Biologically Relevant				Copy Number	FLCN	Amplification				0.0	0.0																					0				FLCN Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Biologically Relevant				Copy Number	NF1	Amplification				0.0	0.0																					0				NF1 Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Biologically Relevant				Copy Number	PRPF8	Amplification				0.0	0.0																					0				PRPF8 Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Biologically Relevant				Copy Number	RAD51D	Amplification				0.0	0.0																					0				RAD51D Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Biologically Relevant				Copy Number	BRCA1	Amplification				0.0	0.0																					0				BRCA1 Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Biologically Relevant				Copy Number	CDK12	Amplification				0.0	0.0																					0				CDK12 Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Biologically Relevant				Copy Number	RUNX1T1	Amplification				0.0	0.0																					0				RUNX1T1 Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Biologically Relevant				Copy Number	ESRP1	Amplification				0.0	0.0																					0				ESRP1 Amplification		KIRP-A4-8630	TCGA-A4-8630-01	
Biologically Relevant				Microsatellite Stability	Supporting variants		ESRP1 Amplification, PRDM2 p.278_278E>EE (Insertion), PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: ESRP1 Amplification, PRDM2 p.278_278E>EE (Insertion), PRDM2 p.703_704insP (Insertion)		KIRP-A4-8630		
